tetano
Editor, Senior Moderator
Sci Rep
. 2024 Jun 5;14(1):12882.
doi: 10.1038/s41598-024-63586-8. Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 disease
Krista E van Meijgaarden[SUP] #[/SUP][SUP] 1 [/SUP], Suzanne van Veen[SUP] #[/SUP][SUP] 1 [/SUP], Roula Tsonaka[SUP] #[/SUP][SUP] 2 [/SUP], Paula Ruibal[SUP] 1 [/SUP], Anna H E Roukens[SUP] 1 [/SUP], Sesmu M Arbous[SUP] 3 [/SUP], Judith Manniën[SUP] 2 [/SUP], Suzanne C Cannegieter[SUP] 4 [/SUP], Tom H M Ottenhoff[SUP] 1 [/SUP], Simone A Joosten[SUP] 5 [/SUP]; BEAT-COVID group; COVID-19 LUMC group
Collaborators, Affiliations
SARS-CoV2 infection results in a range of disease severities, but the underlying differential pathogenesis is still not completely understood. At presentation it remains difficult to estimate and predict severity, in particular, identify individuals at greatest risk of progression towards the most severe disease-states. Here we used advanced models with circulating serum analytes as variables in combination with daily assessment of disease severity using the SCODA-score, not only at single time points but also during the course of disease, to correlate analyte levels and disease severity. We identified a remarkably strong pro-inflammatory cytokine/chemokine profile with high levels for sCD163, CCL20, HGF, CHintinase3like1 and Pentraxin3 in serum which correlated with COVID-19 disease severity and overall outcome. Although precise analyte levels differed, resulting biomarker profiles were highly similar at early and late disease stages, and even during convalescence similar biomarkers were elevated and further included CXCL3, CXCL6 and Osteopontin. Taken together, strong pro-inflammatory marker profiles were identified in patients with COVID-19 disease which correlated with overall outcome and disease severity.
. 2024 Jun 5;14(1):12882.
doi: 10.1038/s41598-024-63586-8. Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 disease
Krista E van Meijgaarden[SUP] #[/SUP][SUP] 1 [/SUP], Suzanne van Veen[SUP] #[/SUP][SUP] 1 [/SUP], Roula Tsonaka[SUP] #[/SUP][SUP] 2 [/SUP], Paula Ruibal[SUP] 1 [/SUP], Anna H E Roukens[SUP] 1 [/SUP], Sesmu M Arbous[SUP] 3 [/SUP], Judith Manniën[SUP] 2 [/SUP], Suzanne C Cannegieter[SUP] 4 [/SUP], Tom H M Ottenhoff[SUP] 1 [/SUP], Simone A Joosten[SUP] 5 [/SUP]; BEAT-COVID group; COVID-19 LUMC group
Collaborators, Affiliations
- PMID: 38839796
- DOI: 10.1038/s41598-024-63586-8
SARS-CoV2 infection results in a range of disease severities, but the underlying differential pathogenesis is still not completely understood. At presentation it remains difficult to estimate and predict severity, in particular, identify individuals at greatest risk of progression towards the most severe disease-states. Here we used advanced models with circulating serum analytes as variables in combination with daily assessment of disease severity using the SCODA-score, not only at single time points but also during the course of disease, to correlate analyte levels and disease severity. We identified a remarkably strong pro-inflammatory cytokine/chemokine profile with high levels for sCD163, CCL20, HGF, CHintinase3like1 and Pentraxin3 in serum which correlated with COVID-19 disease severity and overall outcome. Although precise analyte levels differed, resulting biomarker profiles were highly similar at early and late disease stages, and even during convalescence similar biomarkers were elevated and further included CXCL3, CXCL6 and Osteopontin. Taken together, strong pro-inflammatory marker profiles were identified in patients with COVID-19 disease which correlated with overall outcome and disease severity.